Jim Jung-Ching Lin
University of Iowa
H-index: 74
North America-United States
Top articles of Jim Jung-Ching Lin
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
43P Updated efficacy and circulating tumour (ct) DNA analysis in patients (pts) with TRK fusion lung cancer treated with larotrectinib (laro) | ESMO Open | A Drilon JJ Lin DSW Tan S Kummar JD Patel | 2024/3/1 |
Noninvasive Physiological Measurement: Wireless Microwave Sensing | James C Lin | 2024 | |
666P Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours | Annals of Oncology | S Lu FGM De Braud Y Fan X Hu Y Ohe | 2023/10/1 |
668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer | Annals of Oncology | A Drilon L Shen C van Tilburg F Doz DSW Tan | 2023/10/1 |
15MO Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib | Journal of Thoracic Oncology | M Hoejgaard A Drilon JJ Lin S Kummar DSW Tan | 2023/4/1 |
PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1 | Value in Health | B Sherif B Besse B Solomon L Bazhenova DW Kim | 2023/12/1 |
81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study | Journal of Thoracic Oncology | ML Johnson SH I Ou E Felip C Baik B Besse | 2023/4/1 |
OA03. 06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial | Journal of Thoracic Oncology | BC Cho DR Camidge JJ Lin S-W Kim B Solomon | 2023/11/1 |
EP08. 02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study | Journal of Thoracic Oncology | A Drilon S-HI Ou S Gadgeel M Johnson A Spira | 2022/9/1 |
61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib | Annals of Oncology | V Moreno JJ Lin DSW Tan UN Lassen S Leyvraz | 2022/4/1 |
463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up | Annals of Oncology | RS McDermott C van Tilburg JJ Lin S Kummar DSW Tan | 2022/9/1 |
What Is the Optimal Carrier Fluid Rate for Reliable Hemodynamic Drug Infusion in Neonatal Patients? | Pediatrics | Elayna Ng James Lin | 2022/2/23 |
EP08. 02-148 Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer | Journal of Thoracic Oncology | V Moreno JJ Lin DSW Tan S Kummar M-S Dai | 2022/9/1 |
464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset | Annals of Oncology | A Italiano AE Drilon L Shen DS Hong C van Tilburg | 2022/9/1 |
Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors | European Journal of Cancer | A Drilon B Besse DR Camidge SHI Ou Shirish M Gadgeel | 2022/10/1 |
2021 Most Influential Bioelectromagnetics Journal Paper Award | James C Lin | 2022/9 | |
Grid-stretching capability for the GEOS-Chem 13.0. 0 atmospheric chemistry model, Geosci. Model Dev., 14, 5977–5997 | Geosci. Model Dev. | L Bindle RV Martin MJ Cooper EW Lundgren SD Eastham | 2021 |
1363TiP A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK+ advanced/metastatic NSCLC | Annals of Oncology | BJ Solomon M Millward DW Kim EK Park JJ Lin | 2021/9/1 |
MO01. 33 CRESTONE–clinical study of response to seribantumab in tumors with NEuregulin-1 (NRG1) fusions–a phase 2 study of the anti-HER3 mAb for advanced or metastatic solid … | Journal of Thoracic Oncology | D Spigel SN Waqar ME Burkard JJ Lin YK Chae | 2021/1/1 |
534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status | Annals of Oncology | A Drilon L Shen CM van Tilburg DSW Tan S Kummar | 2021/9/1 |
